Our Noble Purpose

To advance the discovery and development of first-in-class, best-in-class antibody therapeutics to validated targets for markets with significant medical need.

Our Noble Purpose

To advance the discovery and development of first-in-class, best-in-class antibody therapeutics to validated targets for markets with significant medical need.

Home

Bird Rock Bio is a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Backed by leading biotechnology venture investors, our strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best-in-class therapeutic antibodies with significant clinical and commercial differentiation.

News

May 28, 2020
Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases
October 17, 2019
Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease
September 13, 2018
Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease

Noteworthy

Bird Rock Bio, Inc. was founded quidam vocent in, dolores mediocrem periculis ad pri, at possit nominavi constituam vis